GUIDE Sosiete

FDA Predetermined Change Control Plans for AI Devices

An FDA predetermined change control plan (PCCP) describes specified planned modifications to a medical device, how the manufacturer will develop and validate them, and how their effects will be assessed.

Déglul tegtal biiIA-nettali · ~3 min

Ci xët wii3 simili jàng
  1. Résumé
  2. Plongeur bu xóot
  3. Doxal ci àdduna dëgg
  4. The Future of FDA Predetermined Change Control Plans for AI Devices
  5. Teg ko ci jëf
  6. Weyal di banneexu
  7. Laaj yi ñuy faral di laaj

Résumé

FDA reviews an AI-device PCCP as part of a marketing submission. The plan can support defined future changes without a separate submission for each change, within its authorized scope.

Plongeur bu xóot

A PCCP is a planned change-management component of a medical-device marketing submission. FDA’s August 2025 final guidance gives recommendations for PCCPs tailored to AI-enabled device software functions, including the device constituent part of device-led combination products reviewed through 510(k), De Novo, and PMA pathways. FDA reviews the proposed plan with the marketing submission to assess whether the described changes can be made while maintaining a reasonable assurance of safety and effectiveness. A PCCP does not permit unrestricted changes. The guidance organizes the plan around three elements: a description of planned modifications, a modification protocol for developing, validating, and implementing those changes, and an impact assessment addressing benefits and risks. The planned changes need defined boundaries. The protocol should state methods, acceptance criteria, data controls, validation, implementation safeguards, and monitoring appropriate to the device and proposed change. The impact assessment should explain how changes could affect safety and effectiveness, including interactions among modifications. Vague promises to “retrain as needed” do not provide a meaningful boundary or evidence plan. After FDA authorizes a PCCP, a manufacturer may implement modifications that conform to the authorized plan without a new marketing submission for each described modification. It must still follow applicable quality-system, labeling, reporting, and other regulatory obligations. A proposed change outside the PCCP, or one that fails its protocol, requires a separate regulatory assessment. Depending on the change and device pathway, a new 510(k), De Novo, PMA supplement, or other action may be required. PCCP authorization therefore changes the route for a bounded category of updates; it does not exempt a product from device regulation. The 2025 guidance is final agency guidance and expresses FDA’s current recommendations; guidance does not itself establish legally enforceable responsibilities unless specific statutory or regulatory requirements apply. Manufacturers should distinguish this AI-focused guidance from earlier draft documents and from joint international PCCP guiding principles. Align scope, evidence, risk controls, and monitoring with the device and patient context.

Doxal ci àdduna dëgg

A radiology software maker proposes a bounded retraining method, validation protocol, and performance limits for a device intended to detect a defined finding.

A manufacturer specifies which input hardware can be added and how each configuration will be tested before release.

A change to a model’s intended population falls outside the authorized PCCP, so the manufacturer evaluates whether a new marketing submission is required.

A quality team links each released model update to the authorized plan, validation evidence, risk review, and post-market monitoring record.

The Future of FDA Predetermined Change Control Plans for AI Devices

FDA’s guidance supports iterative improvement under defined controls while retaining review of safety and effectiveness. As experience accumulates, agency recommendations, standards, and accepted evidence methods may evolve. Manufacturers should check the current FDA guidance and submission requirements when preparing a plan, and reassess when the device, intended population, or update method changes. A successful PCCP depends on evidence and operational controls after clearance as well as the initial submission. Schedule a review when FDA revises the guidance or the device’s update method changes.

Teg ko ci jëf

Lu tax mu am solo

  • Risk ak kaaraange. Gaañ-gaañu IA yu mag yi ak yu bës bu nekk yépp a ngi aju ci ki xam risk yi ak ki mëna def dara.
  • dogal yu gëna leer. Liggéeyukaay ak xam-xam bu ñépp bokk mooy wane ndax politiku kaaraange bu dëgër mën na am ci wàllu politik.
  • Dagg ci hype. Faram-fàcce yu leer dañuy wàññi li ñuy jàpp ci hype, PR lab, ak tiyaatar bu leerul.

Moytul

  • Jàppale risku nekk gi ni siyaas fiksioŋ fekk kàttan gi dafay yokk.
  • Jaxasoo kaaraange produit surface ak jubluwaay ci suufu autonomie bu kawe.
  • Bàyyi nit ñi xamul làkku Àngle ak ñi xamul làkku Angale, ñu am balluwaay yu baaxul.

Jéego yi ci topp

  1. Tàqale loraange yi ci produit bi, jëfandikoo bu baaxul, ak risku ñàkka mëna yor / ñàkka méngoo.
  2. Laajteel ban firnde mooy soppi sa xalaat ci kalendriye yi ak tar gi.
  3. Danga taamu balluwaay yu njëkk yi ak jàngat yu fëgër yi moo gën waxtaanu njaay mi.
  4. Xaarandil benn yoonu jëf: liggéey, politik, xaalis, wala xam-xam — du xam-xam kese.

Weyal di banneexu

Bulletin bu amul fayda

Jàngal xibaar AI bu bes

Ñatti jaar-jaari IA yuñ firndeel bis bu nekk ci ayu-bis bi, ñu bind leen ci Àngle bu leer. Gratis ba fàww, amul yëgle.

Benn email bis bu nekk ci ayu-bis bi. Benn klik nga dindi abonemaa bi. Dunu musa jaay wala séddoo sa adres.

Nattal sa bopp

Take the FDA Predetermined Change Control Plans for AI Devices quiz

Feedback ci saasi ci bépp tontu, ak sertifikaa buñ mëna séddoo ak ID buñ mëna saytu soo jàllee ci njàng mi.

Tambalil quiz

Jàppale njàngum IA te doo fay. AI Understanding mbootaay la buy def te Yàlla tax — amul yëgle, amul paywall, musul am. Defal ab sarax

Laaj yi ñuy faral di laaj

What is FDA Predetermined Change Control Plans for AI Devices?

An FDA predetermined change control plan (PCCP) describes specified planned modifications to a medical device, how the manufacturer will develop and validate them, and how their effects will be assessed. FDA reviews an AI-device PCCP as part of a marketing submission. The plan can support defined future changes without a separate submission for each change, within its authorized scope.

Which three elements form the core of an AI-device PCCP?

FDA’s final guidance describes planned modifications, a protocol for implementing them, and an assessment of their impact.

When does FDA review a proposed PCCP?

FDA reviews the PCCP as part of the relevant marketing submission.

What does PCCP authorization allow a manufacturer to do?

The plan can support specified future modifications without a new marketing submission for each change, if they follow the authorized plan.

A manufacturer wants to add a new patient population that its PCCP did not describe. What is the appropriate next step?

A change outside the authorized scope needs a regulatory assessment and may require a new submission.

Which version of FDA’s AI-device PCCP guidance is final?

FDA identifies its tailored final guidance as issued in August 2025.